ANAPTYSBIO, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ANAPTYSBIO, INC. (ANAB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $32.17 per share for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-09-21
- ANAPTYSBIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $43.91, a 196.09% increase year-over-year.
- ANAPTYSBIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $14.83, a 30.21% decline year-over-year.
- ANAPTYSBIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $21.25, a 8.60% decline year-over-year.
- ANAPTYSBIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $23.25, a 23.49% decline year-over-year.
- ANAPTYSBIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $14.87, a 31.82% decline from fiscal 2024.
- ANAPTYSBIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $21.81, a 0.95% decline from fiscal 2023.
- ANAPTYSBIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $22.02, a 24.67% decline from fiscal 2022.
- ANAPTYSBIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $29.23, a 0.88% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $32.17 10-KT · filed 2026-09-21 | |||
| 2026-03-31 | $43.91 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $14.87 10-KT · filed 2026-09-21 | |||
| 2025-09-30 | $14.87 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $14.83 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | $14.83 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $21.81 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $21.88 10-Q · filed 2024-11-05 | |||
| 2024-06-30 | $21.45 10-Q · filed 2024-08-05 | |||
| 2024-03-31 | $21.25 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $22.02 10-K · filed 2024-03-11 | |||
| 2023-09-30 | $22.39 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $22.67 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $23.25 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $29.23 10-K · filed 2023-03-01 | |||
| 2022-09-30 | $29.44 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $29.94 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $30.39 10-Q · filed 2022-05-04 | |||
| 2021-12-31 | $29.49 10-K · filed 2022-03-07 | |||
| 2021-09-30 | $29.44 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $29.52 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $29.63 10-Q · filed 2021-05-04 | |||
| 2020-12-31 | $19.13 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $18.30 10-Q · filed 2020-11-04 | |||
| 2020-06-30 | $16.28 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $15.88 10-Q · filed 2020-05-06 | |||
| 2019-12-31 | $34.31 10-K · filed 2020-03-02 | |||
| 2019-09-30 | $67.33 10-Q · filed 2019-11-08 | |||
| 2019-06-30 | $69.02 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $68.90 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | $98.19 10-K · filed 2019-02-28 | |||
| 2018-09-30 | $100.98 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | $105.48 10-Q · filed 2018-08-07 | |||
| 2018-03-31 | $107.05 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | $24.44 10-K · filed 2018-03-05 | |||
| 2017-09-30 | $22.67 10-Q · filed 2017-11-07 | |||
| 2017-06-30 | $22.26 10-Q · filed 2017-08-10 | |||
| 2017-03-31 | $22.13 10-Q · filed 2017-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |